QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

CBIO

QT53Crescent Biopharma, Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
17.69
-0.52-2.86%
OverviewShort InterestFilings
CBIOQT53Crescent Biopharma, Inc.·NASDAQ
OverviewShort InterestFilings
17.69-2.86%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-
Insider Own-
Shs Outstand-
Perf Week-3.54%
Market Cap502.08MForward P/E-EPS next Y-3.25Insider Trans-Shs Float-Perf Month-4.27%
Enterprise Value314.46MPEG0.02EPS next Q-0.78Inst Own-Short Float-Perf Quarter66.57%
Income-147010283.00P/S42.25EPS this Y-Inst Trans-Short Ratio-Perf Half Y36.92%
Sales11.88MP/B3.01EPS next Y-1.49%ROA-81.39%Short Interest-Perf YTD49.16%
Book/sh-P/C-EPS next 5Y-ROE-100.86%52W High27.41 -35.46%Perf Year33.31%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-87.85%52W Low8.72 102.87%Perf 3Y-
Dividend Est.-EV/EBITDA-1.98Sales past 3/5Y- 1.92%Gross Margin100.00%Volatility4.16% 5.85%Perf 5Y-
Dividend TTM-EV/Sales26.46EPS Y/Y TTM-679.29%Oper. Margin-1372.85%ATR (14)1.64Perf 10Y-
Dividend Ex-Date-Quick Ratio13.78Sales Y/Y TTM-Profit Margin-1363.94%RSI (14)44.66Recom2.20
Dividend Gr. 3/5Y-Current Ratio13.78EPS Q/Q-SMA20-6.04%Beta0.68Target Price33.00
Payout0.00%Debt/Eq0.01Sales Q/Q-SMA50-10.73%Rel Volume0.43Prev Close18.21
Employees41LT Debt/Eq0.00EarningsJul 30SMA20023.82%Avg Volume277.96KPrice17.69
IPO DateJan 10, 2014Option/ShortYes / YesEPS/Sales Surpr.17.65% -Net Debt/EBITDA1.18Volume119,469Change-2.86%
Analyst Ratings
DateActionAnalystRatingTarget
Jun-01-26DowngradeHC Wainwright & Co.Buy → Neutral
Feb-26-26ReiteratedStifel NicolausBuy$32 → $29
Jan-28-26InitiatedPiper SandlerOverweight$35
Jan-21-26InitiatedGuggenheimBuy$35
Dec-04-25ReiteratedStifel NicolausBuy$28 → $32
Aug-25-25InitiatedJefferiesBuy$26
Jul-26-24DowngradeTD CowenBuy → Hold
May-06-24DowngradeHC Wainwright & Co.Buy → Neutral
Nov-12-21UpgradeJefferiesHold → Buy
Aug-05-19DowngradeJefferiesBuy → Hold
Latest News
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
FY 2017
12/31/2017
Total Revenue1100
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A000
Gross Profit1100
Selling, General and Administrative Excl. Other251619
Research and Development1382820
Other Operating Expense060
Operating Income-153-50-39
Interest Expense210
Unusual Expense
———
Non-Operating Income (Expense)-3-60
Net Income Before Taxes-152-49-37
Income Taxes200
Consolidated Net Income-154-49-37
Net Income From Continuing Operations-154-49-37
Net Income-154-49-37
EPS (Recurring)-14.78-1.40-0.58
EPS (Basic, Before Extraordinaries)-14.78-1.40-0.58
EPS (Diluted)-14.78-1.40-0.58
EBITDA-150-44-39
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio10.78——
Gross Margin100.00——
Operating Margin-1,390.91——
Net Margin-1,400.00——
Shares Outstanding102063
Market Capitalization119——
Operating Lease Expense
———
Insider Trading Volume
$21.18$18.43$15.69$12.95$10.20● Close Price0.00M4.56M9.12M13.68M18.24MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Fairmount Funds Management LLCdirector, 10 percent owner:Dec 04 '25Buy12.231,491,43418,237,7312,747,866Dec 08 12:00 AM
Invus Public Equities, L.P.10% OwnerAug 08 '24Sale0.19260,87350,0096,317,565Aug 09 12:00 AM
Invus Public Equities, L.P.10% OwnerAug 07 '24Sale0.1861,48811,1976,578,438Aug 09 12:00 AM
Invus Public Equities, L.P.10% OwnerAug 06 '24Sale0.1855,73210,1886,639,926Aug 07 12:00 AM
Invus Public Equities, L.P.10% OwnerAug 05 '24Sale0.19164,52330,9966,695,658Aug 07 12:00 AM
Invus Public Equities, L.P.10% OwnerAug 02 '24Sale0.20286,20057,3546,860,181Aug 05 12:00 AM
Invus Public Equities, L.P.10% OwnerAug 01 '24Sale0.2263,56413,7437,146,381Aug 05 12:00 AM
Invus Public Equities, L.P.10% OwnerJul 30 '24Sale0.22756,835167,1857,209,945Jul 30 12:00 AM
Invus Public Equities, L.P.10% OwnerJul 29 '24Sale0.24363,94985,6377,966,780Jul 30 12:00 AM
Invus Public Equities, L.P.10% OwnerJul 26 '24Sale0.24258,33562,4408,330,729Jul 30 12:00 AM
Rock EdwinChief Medical OfficerJun 21 '24Buy0.27115,00030,717680,403Jun 24 12:00 AM
Rock EdwinChief Medical OfficerJun 20 '24Buy0.25190,00048,108565,403Jun 24 12:00 AM
Hahn Brian M.SVP Finance, CFOJun 18 '24Buy0.2517,5004,33570,643Jun 20 12:00 AM
Rock EdwinChief Medical OfficerSep 22 '23Buy1.3830,40341,956375,403Sep 25 12:00 AM
Rock EdwinChief Medical OfficerSep 21 '23Buy1.3835,00048,300345,000Sep 25 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR